DENALI THERAPEUTICS INC (DNLI)
US24823R1059 - Common Stock
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -427.49M | -145.22M | -326.00M | -290.60M | 71.10M | |||
| Depreciation Amortization | 8.60M | 16.73M | 10.40M | 8.60M | 8.50M | |||
| Change In Working Capital | 12.26M | -289.93M | -24.00M | -23.40M | 286.00M | |||
| Taxes Paid | 3.00K | 3.00K | N/A | N/A | N/A | |||
| Other non cash items | 44.12M | 60.43M | 94.90M | 94.00M | 50.40M | |||
| OPERATING CASH FLOW | -362.67M | -357.99M | -244.70M | -211.40M | 416.20M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -13.06M | -12.94M | -17.80M | -8.50M | -3.10M | |||
| Other Investing Activity | -174.90M | 262.25M | -123.60M | -13.10M | -620.10M | |||
| INVESTING CASH FLOW | -187.96M | 249.31M | -141.40M | -21.60M | -623.20M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | N/A | N/A | N/A | N/A | N/A | |||
| Stock Issued/Repurchased | 517.21M | 17.82M | 310.70M | 19.30M | 634.70M | |||
| Other Financing Activity | N/A | N/A | N/A | N/A | N/A | |||
| FINANCING CASH FLOW | 493.19M | 17.82M | 310.70M | 19.30M | 634.70M | |||
| CHANGE IN CASH | -57.43M | -90.86M | -75.40M | -213.70M | 427.70M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -362.67M | -357.99M | -244.70M | -211.40M | 416.20M | |||
| Capital Expenditure | -13.06M | -12.94M | -17.80M | -8.50M | -3.10M | |||
| FREE CASH FLOW | -375.73M | -370.93M | -262.50M | -219.90M | 413.10M | |||
All data in USD